# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Mayank Mamtani maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from ...
JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $78 price t...
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target f...
JMP Securities analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and lowers the price targe...
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's comme...